149506-34-3

Basic information

• Product Name: 2-(4-broMophenyl)propane-1,3-diol
• Synonyms: 2-(4-broMophenyl)propane-1,3-diol;2-(4-bromophenyl)-1,3-propanediol
• CAS NO: 149506-34-3
• Molecular Formula: C₉H₁₁BrO₂
• Molecular Weight: 231.08644
• Mol File: 149506-34-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-broMophenyl)propane-1,3-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-broMophenyl)propane-1,3-diol(149506-34-3)
• EPA Substance Registry System: 2-(4-broMophenyl)propane-1,3-diol(149506-34-3)

Safety Data

• Hazardous Substances Data: 149506-34-3(Hazardous Substances Data)

Usage

Chemical Class

Phenylpropanoids

Derivative

4-bromophenyl and propane-1,3-diol

Common Uses

Synthesis of pharmaceuticals and biologically active compounds

Potential Properties

Anti-inflammatory, antifungal

Value in Medications and Skincare

Inhibits the growth of certain cancer cells

Potential Applications

Cancer treatment, anti-inflammatory and antifungal medications, skincare products.

Upstream product

• 93139-85-6 2-(4-bromophenyl)malonic acid diethyl ester 
• 709648-68-0 2-(4-bromophenyl)malondialdehyde 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 14062-25-0 Ethyl 4-bromophenylacetate 

Downstream Products

• 1024021-63-3 C₁₂H₁₅BrO₂ 
• 1089131-47-4 Tert-butyl 2-(4-bromophenyl)allyl(4-nitrophenylsulfonyl)carbamate 
• 1089131-52-1 tert-butyl (2-(4-bromophenyl)-3-hydroxypropyl)(4-nitrophenylsulfonyl)carbamate 
• 149506-33-2 1,3-[bis(p-tosyloxy)]-2-(4-bromophenyl)propane 
• 637356-49-1 3-azido-2-(4-bromophenyl)propan-1-ol 

Relevant articles and documents

Enantioselective Desymmetrization of 2-Aryl-1,3-propanediols by Direct O-Alkylation with a Rationally Designed Chiral Hemiboronic Acid Catalyst That Mitigates Substrate Conformational Poisoning

Enantioselective desymmetrization by direct monofunctionalization of prochiral diols is a powerful strategy to prepare valuable synthetic intermediates in high optical purity. Boron acids can activate diols toward nucleophilic additions; however, the design of stable chiral catalysts remains a challenge and highlights the need to identify new chemotypes for this purpose. Herein, the discovery and optimization of a bench-stable chiral 9-hydroxy-9,10-boroxarophenanthrene catalyst is described and applied in the highly enantioselective desymmetrization of 2-aryl-1,3-diols using benzylic electrophiles under operationally simple, ambient conditions. Nucleophilic activation and discrimination of the enantiotopic hydroxy groups on the diol substrate occurs via a defined chairlike six-membered anionic complex with the hemiboronic heterocycle. The optimal binaphthyl-based catalyst 1g features a large aryloxytrityl group to effectively shield one of the two prochiral hydroxy groups on the diol complex, whereas a strategically placed "methyl blocker"on the boroxarophenanthrene unit mitigates the deleterious effect of a competing conformation of the complexed diol that compromised the overall efficiency of the desymmetrization process. This methodology affords monoalkylated products in enantiomeric ratios equal or over 95:5 for a wide range of 1,3-propanediols with various 2-aryl/heteroaryl groups.

3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C-F or the like; R1 represents a C1-C3 alkyl group; Y represents oxygen atom or N-R7; R2, R3, R4, R5, R6 and R7 each independently represents hydrogen atom, a C1-C6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists

A new series of 1,3-dioxane-2-carboxylic acid derivatives was synthesized and evaluated for agonist activity at human peroxisome proliferator-activated receptor (PPAR) subtypes. Structure-activity relationship studies led to the identification of 2-methyl-c-5-[4-(5-methyl-2-phenyl-1,3-oxazol-4-yl)butyl]-1,3-dioxane-r-2-carboxylic acid 4b as a potent PPARα agonist with high subtype selectivity at human receptor subtypes. This compound exhibited a substantial hypolipidemic effect in type 2 diabetic KK-Ay mice.